Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV induction study in Chinese patients with moderately to severely active Crohn's disease
CTR20230980Phase 3Active
- Sponsor
- Takeda
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab, sponsored by Takeda. Started Jul 2023; status: active.
02
Drugs
vedolizumab
Beyond the preview
Go deeper on CTR20230980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230980.